Beijing-Sana
The National Health Commission of China announced that the country has made positive progress in developing monovalent and polyvalent vaccines against the Omicron mutant of the Corona virus.
"Pre-clinical studies of some vaccines have been completed, with progress in clinical trial applications," said Cheng Zhongwei, an official with the committee, as saying today during a press conference, noting that full vaccination is still effective in reducing the risk of hospitalization and severe suffering. of disease and death caused by it.
"China currently has 29 vaccines that have entered the clinical trial phase, with 16 vaccines in the third phase of clinical trials," Zheng said, stressing that seven vaccines have obtained permission for conditional marketing or emergency use, and the WHO emergency use list includes two of these vaccines.
Follow Sana's news on Telegram https://t.me/SyrianArabNewsAgency
